Abstract 1611P
Background
Living with brain metastasis (BM) causes distress for patients and family carers. Patients report a wide range of physical, social and psychological problems that affect daily life for them and their families. Despite the high prevalence of BM, little is known about the experiences of family carers. This qualitative study explores how family carers of BM patients perceive the information and communication about diagnosis, the health care services provided, and how their lives are affected by the BM.
Methods
This was a prospective qualitative study with individual semi-structured interviews. Participants were interviewed three times; shortly after the BM diagnosis, and then after two and four months. A total of 40 interviews with 18 adult family carers (13 spouses, 2 adult children, 2 siblings) were conducted. Transcripts were analysed using a reflexive thematic analysis. A trajectory matrix was developed for the longitudinal design, searching for overarching themes over time as well as changes in the themes identified.
Results
For many family carers the BM diagnosis was experienced as particularly frightening, given that the metastases were located in the brain. Family carers felt that they lived in a rapidly changing, chaotic and unpredictable situation. They reported working nonstop to coordinate family life, the patient’s health care follow-up, and to maintain a sort of normality in daily life. The situation affected their relationship with the patient, especially daily life activities and communication. The need for information was extensive among most family carers. They emphasized a need for more information about treatment and prognosis to be able to plan for the future. This information need remained high through all interviews.
Conclusions
Being a family carer of a patient with BM implies extensive practical, emotional and psychosocial challenges. The need for continuous information is particularly high, and health care providers should tailor their information to the individual recipient. Palliative care, with a person-centred approach and systematic follow up of the needs of family carers, should be introduced in an early stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
The Norwegian Cancer Society Pink Ribbon and The Norwegian South-East Health Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05